KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Research & Development (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Research & Development for 16 consecutive years, with $31.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 56.04% to $31.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.5 million, a 3.09% increase, with the full-year FY2025 number at $81.5 million, up 3.09% from a year prior.
  • Research & Development was $31.9 million for Q4 2025 at Halozyme Therapeutics, up from $17.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.9 million in Q4 2025 to a low of $8.1 million in Q2 2021.
  • A 5-year average of $17.0 million and a median of $17.4 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 123.25% in 2022, then fell 22.56% in 2025.
  • Halozyme Therapeutics' Research & Development stood at $10.1 million in 2021, then surged by 123.25% to $22.6 million in 2022, then dropped by 5.45% to $21.3 million in 2023, then dropped by 4.19% to $20.4 million in 2024, then soared by 56.04% to $31.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Research & Development are $31.9 million (Q4 2025), $17.3 million (Q3 2025), and $17.5 million (Q2 2025).